Veronique Beiss

TL;DR: Current approaches to COVID-19 vaccine development are highlighted, highlighting the role of nanotechnology, manufacturing and distribution and a successful vaccine platform must enable rapid discovery, scalable manufacturing and global distribution.

TL;DR: This review analyzes these frontrunners in the vaccine development space and delves into their posted results while highlighting the role of the nanotechnologies applied by all the vaccine developers.

TL;DR: It is demonstrated that in situ administration of CPMV immunotherapy in the setting of glioma can effectively recruit unique subset of effector innate and adaptive immune cells to the brain parenchyma while reducing immune suppressive cellular population, leading to regression of intracranial gliomas.

TL;DR: It is found that the formulations had similar effects on most secreted cytokines and immune cells, but the RNA-containing CPMV particles were uniquely able to boost populations of potent antigen-presenting cells, such as tumor-infiltrating neutrophils and activated dendritic cells.

TL;DR: The analysis of component-specific efficacy indicates significant differences in IC50 requirements for stage-specific antibody concentrations providing valuable insights into this complex scenario and will improve future approaches towards malaria vaccine cocktail development regarding the selection of suitable antigens and the ratios of components.